Evidence map›Paper›PMID 34696531›Full record

Observational studyViruses2021

Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus.

Aya Ishizaka, Michiko Koga, Taketoshi Mizutani, Lay Ahyoung Lim, Eisuke Adachi, Kazuhiko Ikeuchi, Ryuta Ueda, Haruyo Aoyagi, Satoshi Tanaka, Hiroshi Kiyono and 8 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Aya IshizakaDivision of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.ORCID 0000-0003-2800-2430
Michiko KogaDivision of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.ORCID 0000-0002-3122-9735
Taketoshi MizutaniDivision of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.ORCID 0000-0002-1329-6512
Lay Ahyoung LimDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Eisuke AdachiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.ORCID 0000-0002-1623-873X
Kazuhiko IkeuchiDepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.ORCID 0000-0003-1677-3369
Ryuta UedaDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Haruyo AoyagiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Satoshi TanakaDepartment of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka 540-0006, Japan.ORCID 0000-0003-3950-783X
Hiroshi KiyonoInternational Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0003-3096-6749
Hideki AizakiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Sachiyo YoshioThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba 272-8516, Japan.ORCID 0000-0001-7860-6916
Eiji MitaDepartment of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka 540-0006, Japan.
Masamichi MuramatsuDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0002-0153-3533
Tatsuya KantoThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba 272-8516, Japan.ORCID 0000-0003-4800-6754
Takeya TsutsumiDivision of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Hiroshi YotsuyanagiDivision of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.ORCID 0000-0001-7882-5262
National Institute of Infectious Diseases · JPUniversity of Tokyo Hospital · JPThe University of Tokyo · JPNational Center for Global Health and Medicine · JPOsaka National Hospital · JPThe Dia Foundation for Research on Ageing Societies · JPUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis A virus (HAV) causes transient acute infection, and little is known of viral shedding via the duodenum and into the intestinal environment, including the gut microbiome, from the period of infection until after the recovery of symptoms. Therefore, in this study, we aimed to comprehensively observe the amount of virus excreted into the intestinal tract, the changes in the intestinal microbiome, and the level of inflammation during the healing process. We used blood and stool specimens from patients with human immunodeficiency virus who were infected with HAV during the HAV outbreak in Japan in 2018. Moreover, we observed changes in fecal HAV RNA and quantified the plasma cytokine level and gut microbiome by 16S rRNA analysis from clinical onset to at least 6 months after healing. HAV was detected from clinical onset up to a period of more than 150 days. Immediately after infection, many pro-inflammatory cytokines were elicited, and some cytokines showed different behaviors. The intestinal microbiome changed significantly after infection (dysbiosis), and the dysbiosis continued for a long time after healing. These observations suggest that the immunocompromised state is associated with prolonged viral shedding into the intestinal tract and delayed recovery of the intestinal environment.

Indexed as

AdultDysbiosisFecesGastrointestinal MicrobiomeHepatitis AHepatitis A virusHIV-1HIV InfectionsHumansJapanMaleMiddle AgedRNA, Ribosomal, 16SViral LoadVirus SheddingRNA, Ribosomal, 16SHAVHIVmicrobiome

Identifiers

PMID34696531
PMCPMC8539651
OpenAlexW3206372379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.